{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:49:23Z","timestamp":1761094163774,"version":"build-2065373602"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.bbmt.2015.12.011","type":"journal-article","created":{"date-parts":[[2015,12,23]],"date-time":"2015-12-23T13:17:29Z","timestamp":1450876649000},"page":"475-481","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment in High-Risk\u00a0Breast Cancer: Data from the European Group for\u00a0Blood and Marrow Transplantation Registry"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3987-419X","authenticated-orcid":false,"given":"Massimo","family":"Martino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Lanza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Pavesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"\u00d6zt\u00fcrk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Didier","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rub\u00e9n","family":"Leno N\u00fa\u00f1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry C.","family":"Schouten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Bosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugo","family":"De Giorgi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Generali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Rosti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Ravelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7169-552X","authenticated-orcid":false,"given":"Carmelo","family":"Bengala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Badoglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Pedrazzoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Bregni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2015.12.011_bib1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/jncimonographs\/lgv010","article-title":"High-dose chemotherapy with autologous hematopoietic stem cell transplantation for high-risk primary breast cancer","volume":"51","author":"Pedrazzoli","year":"2015","journal-title":"J\u00a0Natl Cancer Inst Monogr"},{"key":"10.1016\/j.bbmt.2015.12.011_bib2","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1200\/JCO.2004.02.927","article-title":"What is the role of high-dose chemotherapy in the era of targeted therapies?","volume":"22","author":"Hortobagyi","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.12.011_bib3","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/bmt.2012.126","article-title":"Are there still reasons to believe that high-dose chemotherapy has a role in breast cancer management?","volume":"48","author":"Castagna","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.12.011_bib4","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1200\/JCO.1993.11.6.1132","article-title":"High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer","volume":"11","author":"Peters","year":"1993","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.12.011_bib5","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1200\/JCO.1997.15.6.2312","article-title":"Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results","volume":"15","author":"Gianni","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.12.011_bib6","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/sj.bmt.1704153","article-title":"Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990-1999","volume":"32","author":"Pedrazzoli","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.12.011_bib7","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S0140-6736(00)90024-2","article-title":"High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study","volume":"355","author":"Weiss","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2015.12.011_bib8","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/bmt.2014.312","article-title":"Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants","volume":"50","author":"Passweg","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.12.011_bib9","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/S0140-6736(05)67784-7","article-title":"Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial","volume":"366","author":"Nitz","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2015.12.011_bib10","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1093\/annonc\/mdl001","article-title":"Efficacy of high-dose alkylating chemotherapy in HER2\/neu-negative breast cancer","volume":"17","author":"Rodenhuis","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2015.12.011_bib11","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1200\/JCO.2010.32.5910","article-title":"High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials","volume":"20","author":"Berry","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.12.011_bib12","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1200\/JCO.2011.39.7257","article-title":"Dose intensification in hormone receptor-negative and\/or human epidermal growth factor receptor 2-negative high-risk primary breast cancer","volume":"30","author":"De Giorgi","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.12.011_bib13","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1200\/JCO.2011.39.8057","article-title":"High-dose chemotherapy as adjuvant therapy in breast cancer: could there be a survival benefit?","volume":"30","author":"Moroni","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.12.011_bib14","doi-asserted-by":"crossref","first-page":"e33388","DOI":"10.1371\/journal.pone.0033388","article-title":"High-dose chemotherapy followed by autologous stem cell transplantation as a first-line therapy for high-risk primary breast cancer: a meta-analysis","volume":"7","author":"Wang","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bbmt.2015.12.011_bib15","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/cncr.21477","article-title":"Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation","volume":"104","author":"Peccatori","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2015.12.011_bib16","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/sj.bmt.1705940","article-title":"Allogeneic hematopoietic cell transplantation for metastatic breast cancer","volume":"41","author":"Ueno","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.12.011_bib17","series-title":"Encyclopedia of biostatistics","article-title":"Linear rank tests in survival analysis","author":"Harrington","year":"2005"},{"year":"1989","series-title":"Generalized linear models (Chapman & Hall\/CRC monographs on statistics & applied probability)","author":"McCullagh","key":"10.1016\/j.bbmt.2015.12.011_bib18"},{"key":"10.1016\/j.bbmt.2015.12.011_bib19","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.bbmt.2013.12.569","article-title":"Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell support for high-risk primary breast cancer: results from the Italian national registry","volume":"20","author":"Pedrazzoli","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.12.011_bib20","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/bmt.2012.149","article-title":"Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registry","volume":"48","author":"Martino","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.12.011_bib21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1056\/NEJMoa030684","article-title":"Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer","volume":"349","author":"Tallman","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2015.12.011_bib22","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1200\/JCO.2005.10.202","volume":"23","author":"Peters","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.12.011_bib23","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/sj.bmt.1704291","article-title":"Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients","volume":"32","author":"Kr\u00f6ger","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.12.011_bib24","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1200\/JCO.2010.32.5936","article-title":"High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials","volume":"29","author":"Berry","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.12.011_bib25","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1200\/JCO.2005.03.5196","article-title":"Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95","volume":"24","author":"Basser","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.12.011_bib26","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s10549-013-2475-4","article-title":"A\u00a03-gene proliferation score (TOP-FOX-67) can re-classify histological grade-2, ER-positive breast cancers into low- and high-risk prognostic categories","volume":"138","author":"Szekely","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.bbmt.2015.12.011_bib27","doi-asserted-by":"crossref","first-page":"e72219","DOI":"10.1371\/journal.pone.0072219","article-title":"Prognostic significance of ESR1 amplification and ESR1 PvuII, CYP2C19*2, UGT2B15*2 polymorphisms in breast cancer patients","volume":"8","author":"Markiewicz","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bbmt.2015.12.011_bib28","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/annonc\/mdm551","article-title":"Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial","volume":"19","author":"Gluz","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2015.12.011_bib29","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/COC.0b013e3181573e83","article-title":"High-dose chemotherapy for patients with high-risk breast cancer: a clinical and economic assessment using a quality-adjusted survival analysis","volume":"31","author":"Marino","year":"2008","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.12.011_bib30","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/oxfordjournals.annonc.a058733","article-title":"Durability of hematopoiesis following autografting with peripheral blood hematopoietic progenitors","volume":"5","author":"Siena","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2015.12.011_bib31","first-page":"675","article-title":"The evolution of clinical peripheral blood stem cell transplantation","volume":"17","author":"K\u00f6rbling","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.12.011_bib32","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1200\/JCO.1997.15.5.1870","article-title":"High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America","volume":"15","author":"Antman","year":"1997","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879115018789?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879115018789?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:53:56Z","timestamp":1761058436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879115018789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S1083879115018789"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2015.12.011","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment in High-Risk\u00a0Breast Cancer: Data from the European Group for\u00a0Blood and Marrow Transplantation Registry","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2015.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}